Astrazeneca Supports Crowd Sourcing Challenge to Find Cancer Therapies
News Sep 23, 2015
Public release of a data set of this scale is unprecedented and is intended to help advance research into combination cancer therapy across the global scientific community. Its release underscores AstraZeneca’s commitment to open innovation and reinforces the company’s belief that therapeutic combinations have the potential to transform the way cancer is treated.
The DREAM Challenge is an established crowd sourcing effort to examine fundamental questions in biology and medicine using computational approaches. AstraZeneca is partnering with the Wellcome Trust Sanger Institute, the European Bioinformatic Institute, Sage Bionetworks and the DREAM community on the AstraZeneca-Sanger Drug Combination Prediction DREAM Challenge.
Combining cancer therapies offers the potential for increased efficacy over monotherapy and the possibility of overcoming drug resistance. The DREAM Challenge is based on the development of computer models that identify the properties of drugs that make them powerful in combination. The winners will have their predictions for the best combinations of cancer drugs based on their properties submitted for publication in the journal Nature Biotechnology.
The data released by AstraZeneca include around 10,000 tested combinations that measure the ability of drugs to destroy cancer cell lines from different tumour types including colon, lung, and breast cancer. For the same cell lines, the Wellcome Trust Sanger Institute is making genomic data available to DREAM Challenge participants.
Susan Galbraith, Head of the Oncology Innovative Medicines Unit at AstraZeneca, said: “AstraZeneca has a deep and broad oncology development programme assessing combinations of immunotherapies and small molecules to address the significant unmet need across a wide range of cancers. This open innovation research initiative complements our own efforts brilliantly and we are delighted that the findings could be published for the benefit of the global scientific community.”
Big Data Study Targets Genomic Dark Matter from Ocean Floor to Gut FloraNews
An international team led by computational biologist Fran Supek at IRB Barcelona develop a machine learning method to predict unknown gene functions of microbes.The system examines and compares ‘big data’ available on the metagenomes of human and environmental microbiomes.READ MORE
Machine Learning Model Provides Early Dementia DiagnosisNews
Improving dementia care through increased and timely diagnosis is an NHS priority, yet around half of those living with dementia live with the condition unaware. Now a new machine-learning model that scans routinely collected NHS data has shown promising signs of being able to predict undiagnosed dementia in primary care.
ExPecto Patronum! Magical Machine Learning Tool Summons DNA Dark Matter DataNews
A new machine learning framework, dubbed ExPecto, can predict the effects of mutations in the so-called “dark matter” regions of the human genome. ExPecto pinpoints how mutations can disrupt the way genes turn on and off throughout your body.